Zentalis Pharmaceuticals, Inc.
ZNTL Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$2.21
KIRA · Stoqly’s AI analyst, in plain words
- Zentalis Pharmaceuticals, Inc. had $0.0M of revenue in fiscal 2025, down 100.0% on the year before.
- Zentalis Pharmaceuticals, Inc. lost $137M in fiscal 2025.
- Free cash flow was −$125M in fiscal 2025, — of revenue.
- Zentalis Pharmaceuticals, Inc. returned $10.0M to shareholders in fiscal 2025. The diluted share count rose 1.1%.
Market cap
$158M
P/E
—
Revenue
$0.0M
Net income
−$137M
Free cash flow
−$125M
Operating margin
—
Zentalis Pharmaceuticals, Inc. in 30 seconds · fiscal 2025
Are sales growing?
−100.0%
No. Sales fell 100.0% last year.
Does it make a profit?
−$137M
No. It lost money last year.
How healthy are the accounts?
1 / 7
Weak. It passes 1 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Zentalis Pharmaceuticals, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 26, 2026
- Legal name
- Zentalis Pharmaceuticals, Inc.
- CIK
- 0001725160
Zentalis Pharmaceuticals, Inc. · ZNTL
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | — | $0.0M | $0.0M | $67.4M | $0.0M |
| Revenue growth | — | — | — | — | −100.0% |
| Operating margin | — | — | — | −283.6% | — |
| Net income | −$159M | −$237M | −$292M | −$166M | −$137M |
| Net margin | — | — | — | −246.0% | — |
| Diluted EPS | −$3.72 | −$4.48 | −$4.47 | −$2.33 | −$1.91 |
| Cash | |||||
| Cash from operations | −$154M | −$164M | −$208M | −$171M | −$125M |
| Capital expenditure | $6.1M | $2.5M | $0.6M | $0.2M | $0.0M |
| Free cash flow | −$160M | −$166M | −$208M | −$171M | −$125M |
| FCF margin | — | — | — | −253.7% | — |
| Share buybacks | — | — | $0.0M | $0.0M | $10.0M |
| Share count change | 51.8% | 23.8% | 23.7% | 8.7% | 1.1% |
| Debt and strength | |||||
| Cash and short-term investments | $59.7M | $43.1M | $483M | $352M | $246M |
| Shareholders' equity | $364M | $434M | $437M | $337M | $216M |
| Current ratio | 8.0x | 8.0x | 7.2x | 7.3x | 6.9x |
| Returns and quality | |||||
| Return on equity | −47.2% | −59.4% | −67.1% | −42.8% | −49.5% |
| Return on tangible equity | −44.1% | −55.1% | −67.4% | −49.2% | −63.4% |
| Piotroski F-score | — | — | 1 | 3 | 1 |
| Altman Z'' | 2.9 | 2.7 | 0.2 | −2.1 | −9.0 |
Insiders bought, 12 months
$22.9M
1 insider
Insiders sold, 12 months
$10.1M
4 insiders
Of sales under plans
1%
$0.1M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Zentalis Pharmaceuticals, Inc. · ZNTL
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $2.21 a share, the company is worth $158M.
Source: SEC EDGAR XBRL filings (CIK 0001725160). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.